Results 11 to 20 of about 4,214,171 (152)

DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy

Pharmaceutics, 2023
The present review aims to explore the potential targets/partners for future targeted radionuclide therapy (TRT) strategies, wherein cancer cells often are not killed effectively, despite receiving a high average tumor radiation dose.
Honoka Obata, Mikako Ogawa, Michael R. Zalutsky   +2 more
doaj   +2 more sources

Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology [PDF]

Pharmaceutics
Targeted radionuclide therapy (TRT) for internal pathway-directed treatment is a game changer for precision medicine. TRT improves tumor control while minimizing damage to healthy tissue and extends the survival for patients with cancer.
Katsumi Tomiyoshi, Lydia J. Wilson, Firas Mourtada, Jennifer Sims Mourtada, Yuta Namiki, Wataru Kamata, David J. Yang, Tomio Inoue   +7 more
doaj   +3 more sources

Evaluation of radiation damage effects of low-energy Auger and conversion electrons emitted by 134Ce decay using a Monte Carlo method [PDF]

Scientific Reports
Targeted radionuclide therapy (TRT) is a cancer treatment method that delivers radiation to specific tumor cells, enabling efficient tumor cell killing.
Sangho Lee, Wonku Kim, Deokseong Kim, Jungwook Shin, Yoonsuk Huh, Kondapa Naidu Bobba, Robert R. Flavell, Gyuseong Cho, Youngho Seo   +8 more
doaj   +2 more sources

Editorial for the Special Issue “Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design”

Current Issues in Molecular Biology
Targeted radionuclide therapy (TRT) is gaining wide and rapid acceptance in clinical practice as it can deliver alpha or beta irradiation to a tumor-associated target which may be present in the tumor cell itself or in the microenvironment [...]
Carlo Aprile, Onelio Geatti, Letizia Canziani, Lorenzo Lodola   +3 more
doaj   +2 more sources

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research

Pharmaceutics, 2019
Prostate specific membrane antigen (PSMA) has become a major focus point in the research and development of prostate cancer (PCa) imaging and therapeutic strategies using radiolabeled tracers. PSMA has shown to be an excellent target for PCa theranostics
Eline A.M. Ruigrok, Wytske M. van Weerden, Julie Nonnekens, Marion de Jong   +3 more
doaj   +3 more sources

Using advanced cell models for targeted radionuclide therapy evaluation: increased efficacy in 3D versus 2D [PDF]

EJNMMI Research
Background Preclinically, radiopharmaceuticals are currently mainly evaluated in two-dimensional (2D) cell models, which lack clinical features that are relevant for accurate evaluation of targeted radionuclide therapy (TRT) responses. The development of
Maria J. Klomp, Sigrun E. Erkens, Lilian van den Brink, Wytske M. van Weerden, Simone U. Dalm   +4 more
doaj   +2 more sources

EGFR-family expression and implications for targeted radionuclide therapy

, 2008
Summary High expression in the primary tumor of receptors in the EGFR-family is most often also accompanied by a similar high expression in corresponding metastases.
Carlsson, Jörgen,
core   +8 more sources

Head-to-head comparison of [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 efficacy in a PDAC mouse model [PDF]

EJNMMI Research
Background Terbium-161 (Tb-161) emits internal conversion and Auger electrons, in addition to beta-minus radiation, which might be of added benefit for targeted radionuclide therapy (TRT) compared to Lutetium-177 (Lu-177).
Circe D. van der Heide, Carolline M. Ntihabose, Mark Konijnenberg, Hanyue Ma, Debra Stuurman, Corrina de Ridder, Yann Seimbille, Michail C. Doukas, Erik de Blois, Simone U. Dalm   +9 more
doaj   +2 more sources

Context-dependent efficacy of fibroblast activation protein-targeted radionuclide therapy (FAP-TRT): the dual role of CAFs. [PDF]

Eur J Nucl Med Mol Imaging
Abstract Fibroblast activation protein-targeted radionuclide therapy (FAP-TRT) shows promise across multiple cancers, but clinical responses remain variable. Here, we aim to investigate how the presence, abundance, and spatial organisation of FAP-expressing cancer-associated fibroblasts (CAFs) relative to tumour
Wu C, Kurniawan A, Li G, Ming Z, Nijkamp MW, van den Broek E, Noordzij W, Glaudemans AWJM, Antunes IF, Cornelissen B.   +9 more
europepmc   +3 more sources

Application of the Linear-Quadratic model to targeted radionuclide therapy [PDF]

, 2011
PhDThe principal aim of this work was to test the hypothesis that the Linear-Quadratic (LQ) model of cell survival, developed for external beam radiotherapy (EBRT), could be extended to targeted radionuclide therapy (TRT) in order to predict dose ...
Murray, Iain
core   +4 more sources